The GotStocks Podcast

IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The GotStocks Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The GotStocks Podcast puts the small-cap sector in the limelight with in-depth interviews featuring executives responsible for guiding gems that could be on the cusp of huge moves. The latest episode features Joel Fruendt, President and CEO of SenesTech Inc. (NASDAQ: SNES), the leader in fertility control to manage animal pest populations.

To begin the interview, Fruendt provided an introduction to SenesTech® and its business model.

“SenesTech is a biotech and life sciences company. Our mission is to improve public health by managing animal pest populations through fertility control, particularly one of the world's oldest issues – rodent control,” Fruendt said. “Right now, we have labels for rats and mice, and we attack the problem at its root cause – reproduction. In essence, what we're doing is rodent birth control. Many cities and other government agencies are trying to control rodent problems by poisoning and killing and trapping and all those things. We're a little bit different in that respect.”

“I'll start out with this fact that usually leaves people with their jaws dropping: two rats, in one year, can become 15,000. That is really the basis for our product. You cannot poison, trap or drown rats fast enough without addressing the reproductive rate, and that is really why our product is in the news a lot right now and why we're getting such success out in the marketplace.”

“SenesTech started as a research company looking at compounds that would mimic menopause. The company came across something that was developed into a product called ContraPest®. It’s a patented technology that really reduces or eliminates fertility in both females and males. It's proven itself out in the field, and we introduced some different delivery systems in order to be more focused on how rats are in the marketplace, whether they're in their burrows or they're roof rats. We have very loyal customers that love the product, so it's an attractive solution for them.”

Join IBN’s Carmel Fisher and Joel Fruendt, President and CEO of SenesTech Inc., to learn more about the company’s newest offering, Evolve™, a soft bait product offering similar efficacy to ContraPest with a number of competitive advantages.

To hear the episode and subscribe for future podcasts, visit https://podcast.gotstocks.net

The latest installment of The GotStocks Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The GotStocks Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The GotStocks Podcast puts the small-cap sector in the limelight with in-depth interviews featuring executives responsible for guiding gems that could be on the cusp of huge moves. The latest episode features Joel Fruendt, President and CEO of SenesTech Inc. (NASDAQ: SNES), the leader in fertility control to manage animal pest populations.

To begin the interview, Fruendt provided an introduction to SenesTech® and its business model.

“SenesTech is a biotech and life sciences company. Our mission is to improve public health by managing animal pest populations through fertility control, particularly one of the world's oldest issues – rodent control,” Fruendt said. “Right now, we have labels for rats and mice, and we attack the problem at its root cause – reproduction. In essence, what we're doing is rodent birth control. Many cities and other government agencies are trying to control rodent problems by poisoning and killing and trapping and all those things. We're a little bit different in that respect.”

“I'll start out with this fact that usually leaves people with their jaws dropping: two rats, in one year, can become 15,000. That is really the basis for our product. You cannot poison, trap or drown rats fast enough without addressing the reproductive rate, and that is really why our product is in the news a lot right now and why we're getting such success out in the marketplace.”

“SenesTech started as a research company looking at compounds that would mimic menopause. The company came across something that was developed into a product called ContraPest®. It’s a patented technology that really reduces or eliminates fertility in both females and males. It's proven itself out in the field, and we introduced some different delivery systems in order to be more focused on how rats are in the marketplace, whether they're in their burrows or they're roof rats. We have very loyal customers that love the product, so it's an attractive solution for them.”

Join IBN’s Carmel Fisher and Joel Fruendt, President and CEO of SenesTech Inc., to learn more about the company’s newest offering, Evolve™, a soft bait product offering similar efficacy to ContraPest with a number of competitive advantages.

To hear the episode and subscribe for future podcasts, visit https://podcast.gotstocks.net

The latest installment of The GotStocks Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

Nextech3D.AI (OTCQX:NEXCF) (CSE:NTAR) (FSE:1SS) recently announced that it is launching the next era of GPT AI 3D product solutions of proprietary Artificial Intelligence (AI) algorithms. The initiative will be led by former Microsoft Executive Hareesh Achi, who is Nextech3D.ai’s current Head of Product Operations.

The Company believes that the AI opportunity is in the early stages, and that the shift from 2D to 3D modeling for e-commerce is part of a major multi-decade transformation that is being led by AI. The Company is working on annual enterprise licensing deals for its suite of GPT AI solutions for 3D models and 3D maps.

“I am thrilled about the exciting developments taking place at Nextech, where we are harnessing the power of our advanced AI technology stack to create innovative 3D GPT tools that significantly enhance productivity and make it easy to create 3D environments that complement the growth of augmented reality and virtual reality marketplaces,” Achi stated in the news release. “In addition to this, we are dedicated to sharing our extensive 3D expertise with both clients and partners alike. It brings me great joy to anticipate the diverse array of 3D creators who will be able to leverage our cutting-edge technology, empowering them to craft extraordinary 3D experiences.”

To read the original press release, visit: https://nnw.fm/H4iQF

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

Nextech3D.AI (OTCQX:NEXCF) (CSE:NTAR) (FSE:1SS) recently announced that it is launching the next era of GPT AI 3D product solutions of proprietary Artificial Intelligence (AI) algorithms. The initiative will be led by former Microsoft Executive Hareesh Achi, who is Nextech3D.ai’s current Head of Product Operations.

The Company believes that the AI opportunity is in the early stages, and that the shift from 2D to 3D modeling for e-commerce is part of a major multi-decade transformation that is being led by AI. The Company is working on annual enterprise licensing deals for its suite of GPT AI solutions for 3D models and 3D maps.

“I am thrilled about the exciting developments taking place at Nextech, where we are harnessing the power of our advanced AI technology stack to create innovative 3D GPT tools that significantly enhance productivity and make it easy to create 3D environments that complement the growth of augmented reality and virtual reality marketplaces,” Achi stated in the news release. “In addition to this, we are dedicated to sharing our extensive 3D expertise with both clients and partners alike. It brings me great joy to anticipate the diverse array of 3D creators who will be able to leverage our cutting-edge technology, empowering them to craft extraordinary 3D experiences.”

To read the original press release, visit: https://nnw.fm/H4iQF

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

Vision Marine Technologies Inc. (NASDAQ: VMAR) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.  

To view the full publication, “The Electrifying Rise of Electric Boats,” please visit: https://nnw.fm/XziTP   

The raucous rumble of combustion engines is fading, systematically replaced by the high-performance hum of electric propulsion that’s transforming every aspect of transport. Electric cars have moved mainstream with both automakers and upstarts offering multiple mobility options. Now another market is being disrupted, as sleek electric boats glide across the water leaving nothing but a whisper of ripples in their wake.    

This surge in electrification isn't just about a clean and green conscience; it's about performance, convenience and a technological transition in mobility that may be as profound as the shift from the horse to the horseless carriage. The producer of the world’s most powerful and most technically advanced electric outboard motor on the market today, Vision Marine Technologies Inc. (NASDAQ: VMAR) (Profile), is a recognized global leader, innovator and disruptive force in the electrification of recreational boating.   

About Vision Marine Technologies Inc.  

Vision Marine Technologies is a leader in the marine industry’s shift to electric propulsion and is at the vanguard of this transformation. The company’s pioneering E-Motion(TM) outboard powertrain system represents a significant leap in marine technology. As a champion of ecofriendly electric powerboats, the company is not just participating in the industry’s evolution, it is driving it. The company’s Flagship E-Motion(TM) 180E electric marine powertrain is the first fully electric, purpose-built outboard powertrain system that combines an advanced battery pack, inverter and high-efficiency motor with proprietary union assembly between the transmission and the electric-motor design utilizing extensive control software. VMAR’s E-Motion and related technologies used in this powertrain system are uniquely designed to improve the efficiency of the outboard powertrain and, as a result, enhance both range and performance. Vision Marine continues to design, innovate, manufacture and sell handcrafted, environmentally friendly, electric recreational boats to customers. The design and technology applied to its boats result in far greater enhanced performance in general as well as higher speeds, longer range and a smoother ride than a traditional internal combustion engine (“ICE”) motorboat.   

For more information about the company, please visit www.VisionMarineTechnologies.com. 

Vision Marine Technologies Inc. (NASDAQ: VMAR) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.  

To view the full publication, “The Electrifying Rise of Electric Boats,” please visit: https://nnw.fm/XziTP   

The raucous rumble of combustion engines is fading, systematically replaced by the high-performance hum of electric propulsion that’s transforming every aspect of transport. Electric cars have moved mainstream with both automakers and upstarts offering multiple mobility options. Now another market is being disrupted, as sleek electric boats glide across the water leaving nothing but a whisper of ripples in their wake.    

This surge in electrification isn't just about a clean and green conscience; it's about performance, convenience and a technological transition in mobility that may be as profound as the shift from the horse to the horseless carriage. The producer of the world’s most powerful and most technically advanced electric outboard motor on the market today, Vision Marine Technologies Inc. (NASDAQ: VMAR) (Profile), is a recognized global leader, innovator and disruptive force in the electrification of recreational boating.   

About Vision Marine Technologies Inc.  

Vision Marine Technologies is a leader in the marine industry’s shift to electric propulsion and is at the vanguard of this transformation. The company’s pioneering E-Motion(TM) outboard powertrain system represents a significant leap in marine technology. As a champion of ecofriendly electric powerboats, the company is not just participating in the industry’s evolution, it is driving it. The company’s Flagship E-Motion(TM) 180E electric marine powertrain is the first fully electric, purpose-built outboard powertrain system that combines an advanced battery pack, inverter and high-efficiency motor with proprietary union assembly between the transmission and the electric-motor design utilizing extensive control software. VMAR’s E-Motion and related technologies used in this powertrain system are uniquely designed to improve the efficiency of the outboard powertrain and, as a result, enhance both range and performance. Vision Marine continues to design, innovate, manufacture and sell handcrafted, environmentally friendly, electric recreational boats to customers. The design and technology applied to its boats result in far greater enhanced performance in general as well as higher speeds, longer range and a smoother ride than a traditional internal combustion engine (“ICE”) motorboat.   

For more information about the company, please visit www.VisionMarineTechnologies.com. 

Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) (“Alarum” or the “Company”), a global provider of internet access and web data collection solutions, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio news release covers the recent announcement that the Company anticipates reporting record revenue and operating cashflow for the fourth quarter of 2023.

"Alarum is pleased to start 2024 with a strong growth momentum, following the year 2023. We intend to continue supporting our future growth also by expanding our offering in the data collection market and launch new innovative products," Shachar Daniel, Chief Executive Officer of Alarum, stated in the news release.

"The amazing results we achieved in the fourth quarter of 2023 emphasize the positive impact advanced by the strategic business changes we implemented during 2023, which are fostering growth and success. Following our decision to focus on improved profitability and reduce investments in the consumer segment, we anticipated that most of our fourth-quarter revenues will be generated by NetNut. These revenues alone surpass the combined revenue of both NetNut and consumer segments from previous periods," Daniel added. "During the fourth quarter, we also increased our cashflow from operating activities and continued our focus on being a profitable growth company."

To read the original press release, visit: https://www.nnw.fm/W9zk8

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) (“Alarum” or the “Company”), a global provider of internet access and web data collection solutions, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio news release covers the recent announcement that the Company anticipates reporting record revenue and operating cashflow for the fourth quarter of 2023.

"Alarum is pleased to start 2024 with a strong growth momentum, following the year 2023. We intend to continue supporting our future growth also by expanding our offering in the data collection market and launch new innovative products," Shachar Daniel, Chief Executive Officer of Alarum, stated in the news release.

"The amazing results we achieved in the fourth quarter of 2023 emphasize the positive impact advanced by the strategic business changes we implemented during 2023, which are fostering growth and success. Following our decision to focus on improved profitability and reduce investments in the consumer segment, we anticipated that most of our fourth-quarter revenues will be generated by NetNut. These revenues alone surpass the combined revenue of both NetNut and consumer segments from previous periods," Daniel added. "During the fourth quarter, we also increased our cashflow from operating activities and continued our focus on being a profitable growth company."

To read the original press release, visit: https://www.nnw.fm/W9zk8

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

The GotStocks Podcast’s latest audio production features Charlie Napolitano, Managing Director of DealFlow Events, a premier conference organizer that has hosted hundreds of in-person and virtual events covering a wide array of business and investment topics. 

To begin the interview, Napolitano provided an introduction to DealFlow Events and its upcoming conference schedule. 

“DealFlow focuses on events in the capital markets and we've been focused on that for 21 years with events taking place globally,” Napolitano said. “We’re excited for this next event that we have coming up January 30th through February 1st, which is called The Microcap Conference, in Atlantic City.” 

“Launching [a microcap-focused conference] is something we've been thinking about for quite a while. And we've always been looking for the right time and the right place to host it. And now personally, I go to Atlantic City 5-6 times a year. I'm a big poker guy and when I was down there, it just kind of felt like an untapped resource… As an event company, whose sole purpose is to bring people together into one space, we felt like in the Northeast, we could host something, bring value and bring people to what I think is a great place to have fun.” 

Napolitano then discussed ways that attendees can make the most of their time at DealFlow conferences. 

“I think the first thing that investors can do is take a look at the website or go into MeetMax and start scheduling meetings with companies… They can, right away, schedule time to sit with those people before their calendars fill… Other than just the one-on-one meetings, we have companies presenting as well, and I think that investors would find value from sitting down and hearing from these companies in that sort of setting… The companies that people can expect to have there range from market caps of $30 million to $500 million. We have a couple that are as high as $900 million, and we have some that are in the $10-12 million range, which we found were interesting and good growth opportunities.” 

Join IBN’s Jonathan Keim and The GotStocks Podcast’s latest guest to learn more about the upcoming Microcap Conference, including highlights like the wild west after party and a poker tournament.

The GotStocks Podcast’s latest audio production features Charlie Napolitano, Managing Director of DealFlow Events, a premier conference organizer that has hosted hundreds of in-person and virtual events covering a wide array of business and investment topics. 

To begin the interview, Napolitano provided an introduction to DealFlow Events and its upcoming conference schedule. 

“DealFlow focuses on events in the capital markets and we've been focused on that for 21 years with events taking place globally,” Napolitano said. “We’re excited for this next event that we have coming up January 30th through February 1st, which is called The Microcap Conference, in Atlantic City.” 

“Launching [a microcap-focused conference] is something we've been thinking about for quite a while. And we've always been looking for the right time and the right place to host it. And now personally, I go to Atlantic City 5-6 times a year. I'm a big poker guy and when I was down there, it just kind of felt like an untapped resource… As an event company, whose sole purpose is to bring people together into one space, we felt like in the Northeast, we could host something, bring value and bring people to what I think is a great place to have fun.” 

Napolitano then discussed ways that attendees can make the most of their time at DealFlow conferences. 

“I think the first thing that investors can do is take a look at the website or go into MeetMax and start scheduling meetings with companies… They can, right away, schedule time to sit with those people before their calendars fill… Other than just the one-on-one meetings, we have companies presenting as well, and I think that investors would find value from sitting down and hearing from these companies in that sort of setting… The companies that people can expect to have there range from market caps of $30 million to $500 million. We have a couple that are as high as $900 million, and we have some that are in the $10-12 million range, which we found were interesting and good growth opportunities.” 

Join IBN’s Jonathan Keim and The GotStocks Podcast’s latest guest to learn more about the upcoming Microcap Conference, including highlights like the wild west after party and a poker tournament.

The GotStocks Podcast’s latest audio production features Jason Fishman, Co-Founder and CEO of Digital Niche Agency (DNA), a digital marketing service leveraging strategic advertising, content marketing and outreach to effectively raise capital.

To begin the interview, Fishman discussed his background in marketing.

“I started as a growth marketer and launched a firm back in 2014 – DNA, which stands for Digital Niche Agency. I had a long stint in ad tech as part of my growth marketing career before this and wanted to work with startup to mid-market organizations versus just the Fortune 500s that I had been a part of,” Fishman said. “Working with early stage to mid-market organizations, I found a commonality of fundraising: there was always some part of the discussion that included capital raise.”

“I was then introduced to 506(c) Reg D fundraising, which allowed for solicitation. It allowed me to market, use my advertising background, content marketing, or outreach programs that we were doing for clients, and apply them to investors. Business-to-investor marketing became our focus at that point. Suddenly, we were able to address this obstacle that each group was running into. I was able to tap into some different data partnerships that I had in the ad tech world to reach high net worth, high household income audiences across various investor behavior subsets, and we saw success on initial campaigns.”

“I was told about Reg CF, regulation crowdfunding, and that it was not a matter of if but when and how we were going to be able to reach retail, not accredited investors – virtually any adult – for these initiatives. We were brought in for the first campaigns. We had advertising live back in May 2016, day one of Reg CF. To date, I have worked on over 350 equity crowdfunding campaigns alone. We started work on regulation A campaigns later that year, as well… We've also worked with digital asset exchanges. Those have been some of our largest clients to date. Basically, anywhere we're targeting investors and bringing them down marketing funnels, we've been able to shine.”

Join IBN’s Jonathan Keim and The GotStocks Podcast’s latest guest to learn more about the trends driving the digital marketing space forward.

The GotStocks Podcast’s latest audio production features Jason Fishman, Co-Founder and CEO of Digital Niche Agency (DNA), a digital marketing service leveraging strategic advertising, content marketing and outreach to effectively raise capital.

To begin the interview, Fishman discussed his background in marketing.

“I started as a growth marketer and launched a firm back in 2014 – DNA, which stands for Digital Niche Agency. I had a long stint in ad tech as part of my growth marketing career before this and wanted to work with startup to mid-market organizations versus just the Fortune 500s that I had been a part of,” Fishman said. “Working with early stage to mid-market organizations, I found a commonality of fundraising: there was always some part of the discussion that included capital raise.”

“I was then introduced to 506(c) Reg D fundraising, which allowed for solicitation. It allowed me to market, use my advertising background, content marketing, or outreach programs that we were doing for clients, and apply them to investors. Business-to-investor marketing became our focus at that point. Suddenly, we were able to address this obstacle that each group was running into. I was able to tap into some different data partnerships that I had in the ad tech world to reach high net worth, high household income audiences across various investor behavior subsets, and we saw success on initial campaigns.”

“I was told about Reg CF, regulation crowdfunding, and that it was not a matter of if but when and how we were going to be able to reach retail, not accredited investors – virtually any adult – for these initiatives. We were brought in for the first campaigns. We had advertising live back in May 2016, day one of Reg CF. To date, I have worked on over 350 equity crowdfunding campaigns alone. We started work on regulation A campaigns later that year, as well… We've also worked with digital asset exchanges. Those have been some of our largest clients to date. Basically, anywhere we're targeting investors and bringing them down marketing funnels, we've been able to shine.”

Join IBN’s Jonathan Keim and The GotStocks Podcast’s latest guest to learn more about the trends driving the digital marketing space forward.

ev Transportation Services (“evTS”) is a specialty vehicle OEM that produces purpose built, all-electric lightweight commercial utility vehicles and fleet management solutions. The Boston-based company is currently focused on the essential services transportation and urban mobility markets, which represent an annual domestic replacement market of approximately 100,000 vehicles, or roughly $2.5 billion annually. End-user applications for the company’s vehicles include, among others, parking enforcement, security patrol, utility meter reading, property and building management, sanitation, airports, seaports, university and corporate campuses, warehouses and fulfilment, and last mile on-demand urban delivery. For more information, visit the company’s website at www.evTS.com.

ev Transportation Services (“evTS”) is a specialty vehicle OEM that produces purpose built, all-electric lightweight commercial utility vehicles and fleet management solutions. The Boston-based company is currently focused on the essential services transportation and urban mobility markets, which represent an annual domestic replacement market of approximately 100,000 vehicles, or roughly $2.5 billion annually. End-user applications for the company’s vehicles include, among others, parking enforcement, security patrol, utility meter reading, property and building management, sanitation, airports, seaports, university and corporate campuses, warehouses and fulfilment, and last mile on-demand urban delivery. For more information, visit the company’s website at www.evTS.com.

Energy Fuels (NYSE American: UUUU) (TSX: EFR) is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and anticipates commencing commercial production of rare earth element (“REE”) carbonate in 2021. Its corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, has the ability to produce vanadium when market conditions warrant and is completing final test-work for the production of REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.”

Energy Fuels (NYSE American: UUUU) (TSX: EFR) is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and anticipates commencing commercial production of rare earth element (“REE”) carbonate in 2021. Its corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, has the ability to produce vanadium when market conditions warrant and is completing final test-work for the production of REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.”

LOS ANGELES (December 16, 2020) – via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces that John Climaco, Chairman and CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), recently appeared on the Want Money Got Money Podcast, a series that helps entrepreneurs learn from the stories, secrets and skills of the world’s most brilliant and interesting startup founders and investors.

The podcast, hosted by Author, Founder, Speaker and CEO Sam Kamani, is available for on-demand listening at https://samkamani.buzzsprout.com. During the interview, Climaco discussed the research of CNS Pharmaceuticals founder Dr. Waldemar Priebe into the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. He also provided an overview of the company’s lead drug candidate, Berubicin, which is proposed for the treatment of GBM. Berubicin has been evaluated in a Phase I clinical trial, where 44% of patients experienced a clinical benefit of stable disease or better, including one patient who experienced a durable complete response and remains cancer free 14 years after treatment. CNS has applied to the U.S. Food and Drug Administration to begin a Phase II clinical trial and expects to begin enrolling patients in this trial in the first quarter of 2021. 

LOS ANGELES (December 16, 2020) – via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces that John Climaco, Chairman and CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), recently appeared on the Want Money Got Money Podcast, a series that helps entrepreneurs learn from the stories, secrets and skills of the world’s most brilliant and interesting startup founders and investors.

The podcast, hosted by Author, Founder, Speaker and CEO Sam Kamani, is available for on-demand listening at https://samkamani.buzzsprout.com. During the interview, Climaco discussed the research of CNS Pharmaceuticals founder Dr. Waldemar Priebe into the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. He also provided an overview of the company’s lead drug candidate, Berubicin, which is proposed for the treatment of GBM. Berubicin has been evaluated in a Phase I clinical trial, where 44% of patients experienced a clinical benefit of stable disease or better, including one patient who experienced a durable complete response and remains cancer free 14 years after treatment. CNS has applied to the U.S. Food and Drug Administration to begin a Phase II clinical trial and expects to begin enrolling patients in this trial in the first quarter of 2021. 

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently appeared on Gamechangers LIVE, a podcast series that shines a spotlight on gamechangers in various industries, sharing perspective on journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. During the interview, CNSP’s chairman and CEO, John Climaco, provided an overview of CNS Pharmaceuticals and its lead drug candidate, Berubicin. Proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer, Berubicin was evaluated in a Phase I clinical trial. As a result of the trial, 44% of patients experienced a clinical benefit of stable disease or better, including one patient who experienced a durable complete response and remains cancer free 14 years after treatment. CNS recently submitted an Investigational New Drug (“IND”) application with the FDA, and, pending approval, it intends to commence a pivotal Phase II clinical trial in the U.S. “I have done all kinds of different things in my career, been in the health care industry for a long time. This is the most exciting thing that I’ve done,” Climaco said in the interview. “This company and our lead product have the potential to really change the landscape and the game in an area of oncology that hasn’t seen a lot of hope for a very long time in glioblastoma.”

To view the full press release, visit https://nnw.fm/jfjZB

CNS Pharmaceuticals (NASDAQ: CNSP) is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. 

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently appeared on Gamechangers LIVE, a podcast series that shines a spotlight on gamechangers in various industries, sharing perspective on journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. During the interview, CNSP’s chairman and CEO, John Climaco, provided an overview of CNS Pharmaceuticals and its lead drug candidate, Berubicin. Proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer, Berubicin was evaluated in a Phase I clinical trial. As a result of the trial, 44% of patients experienced a clinical benefit of stable disease or better, including one patient who experienced a durable complete response and remains cancer free 14 years after treatment. CNS recently submitted an Investigational New Drug (“IND”) application with the FDA, and, pending approval, it intends to commence a pivotal Phase II clinical trial in the U.S. “I have done all kinds of different things in my career, been in the health care industry for a long time. This is the most exciting thing that I’ve done,” Climaco said in the interview. “This company and our lead product have the potential to really change the landscape and the game in an area of oncology that hasn’t seen a lot of hope for a very long time in glioblastoma.”

To view the full press release, visit https://nnw.fm/jfjZB

CNS Pharmaceuticals (NASDAQ: CNSP) is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation.